Trulieve Cannabis (TRLV) Capital Expenditures (2020 - 2026)

Trulieve Cannabis (TRLV) has reported Capital Expenditures for 7 consecutive years, with $4.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Capital Expenditures rose 63.29% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $5.5 million (up 175.61% YoY), while the FY2025 annual figure was $3.7 million, down 30.34% from the prior year.
• Capital Expenditures came in at $4.7 million for Q1 2026 at Trulieve Cannabis, up from -$8.9 million in the prior quarter.
• The five-year high for Capital Expenditures was $90.7 million in Q2 2022, with the low at -$126.5 million in Q4 2022.
• Average Capital Expenditures over 5 years is $1.7 million, with a median of $3.4 million recorded in 2023.
• Across the five-year window, Capital Expenditures surged 9574.6% in 2022 and slumped 2694.47% in 2024, its largest moves.
• Year by year, Capital Expenditures stood at -$126.5 million in 2022, then surged by 102.27% to $2.9 million in 2023, then plunged by 2694.47% to -$74.6 million in 2024, then jumped by 88.05% to -$8.9 million in 2025, then surged by 152.28% to $4.7 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $4.7 million, -$8.9 million, and $11.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.